Results 181 to 190 of about 245,298 (381)

The Growing Burden of Obesity: Addressing a Global Public Health Challenge

open access: yes
United European Gastroenterology Journal, EarlyView.
Patrizia Burra   +11 more
wiley   +1 more source

Gastrointestinal Barrier Disruption in Post‐COVID Syndrome Fatigue Patients

open access: yesAllergy, EarlyView.
Gastrointestinal (GI) barrier disruption in the context of SARS‐CoV‐2 infection is associated with the development of Post‐COVID Syndrome (PCS) Fatigue. Pre‐existing GI complaints may predispose to fatigue development. Monitoring GI symptoms and markers before, during, and after SARS‐CoV‐2 infection is crucial for identifying predictive clinical ...
Johanna Rohrhofer   +8 more
wiley   +1 more source

What is the best treatment for gastroesophageal reflux and vomiting in infants? [PDF]

open access: yes, 2005
The literature on pediatric reflux can be divided into studies addressing clinically apparent reflux (vomiting or regurgitation) and reflux as measured by pH probe or other methods.
McPherson, Vanessa, Wright, Sarah Towner
core  

Gastroesophageal reflux disease (GERD)

open access: yesCleveland Clinic journal of medicine, 2019
Kaitlyn Newkirk
semanticscholar   +1 more source

Mepolizumab Effectiveness in Severe Asthma With/Without Chronic Rhinosinusitis With Nasal Polyps: Real‐World Pooled Analysis

open access: yesAllergy, EarlyView.
MEPOLYP was a pooled analysis of 1037 patients with SAEP[±]CRSwNP. Mepolizumab was associated with a reduction in CSEs, OCS use, and BEC, and improved lung function and ACT score. Over 47% of patients fulfilled ≥ 3 clinical remission criteria. When compared, there was a 30.0% incremental benefit of mepolizumab in reducing CSEs for patients with SAEP ...
Florence Schleich   +14 more
wiley   +1 more source

Infant Acid‐Suppressant Medication, C. difficile Colonisation, and Childhood Body Mass Index in a Canadian Cohort

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim To determine relationships between paediatric use of acid‐suppressive medications (ASMs) (proton pump inhibitors (PPI) and histamine‐2 receptor antagonists (H2RA)) and preschool body mass index (BMI) and mediation by C. difficile colonisation. Methods ASMs were parent‐reported at age 3, 6 and 12 months in 1025 infants from the CHILD Cohort
Sarah L. Bridgman   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy